What’s a McRib anyway? McDonald’s faces lawsuit over sandwich’s ingredients

A proposed class-action suit filed Dec. 23 in the U.S. District Court for the Northern District of Illinois alleges McDonald’s deceptively markets the McRib as containing rib meat while the patty is a boneless, restructured pork product made from various cuts; plaintiffs seek class status, damages and injunctive relief. McDonald’s denies the claims, reiterating the McRib is made with 100% pork; the case could proceed through motions to dismiss or settlement but is unlikely to be materially market-moving absent large damages or regulatory rulings. The McRib returned in Nov. 2025 at select locations (priced roughly $4–$8) and the dispute centers on marketing, labeling and reasonable consumer expectations rather than disclosed ingredient lists.

Analysis

Market structure: The lawsuit is a reputational/legal event concentrated on McDonald’s (MCD) brand elasticity for a niche, episodic product; direct winners are defensive staples and other QSRs that can lean into “authenticity” messaging, while McDonald’s risks a short-term margin hit from reduced promotional pricing power on limited-time items. Expect little immediate commodity impact (lean hog futures unchanged) but a small widening in MCD credit spread (5–15 bps) and a 10–30% bump in near-term options IV if headlines persist over 1–4 weeks.

Risk assessment: Tail risks include class certification or multi-state regulatory action forcing labeling changes and modest fines: low probability but >$50–150M downside to MCD over 12–24 months if punitive damages or industry-wide labeling rules follow. Hidden dependencies include franchisee margins and supplier contracts (restructured meat supply chain) which could increase COGS by 1–2% if compliance/regulation tightens; catalysts are certification rulings (30–90 days) and any FTC/state AG inquiries.

Trade implications: Tactical trades: small, conviction-weighted long in MCD (2–3% portfolio) looking for mean reversion after headline digestion; hedge with a 3-month 5% OTM put spread sized to protect 1–2% portfolio downside, executed within 7–14 days. Rotate 1–2% into KO and UL (defensive staples) to capture flows away from branded “authenticity” risk; consider a short 0.5–1% position in small-cap branded players exposed to labeling suits (POM) where legal/reputational risk is binary.

Contrarian view: Consensus will treat this as immaterial—that’s likely correct for long-term brand fatigue—but markets may overreact to early litigation headlines, creating a buying window for MCD; conversely, if a state AG joins or a preliminary injunction/settlement >$100M surfaces, the initial complacency will reverse. Historical parallels (Subway tuna, Minute Maid pomegranate) show most cases settle or get dismissed; position sizing should assume a 1–3% equity move and cap losses at that level.

Key Decisions for Investors

• Establish a 2–3% long position in MCD within 1–2 weeks to capture likely mean reversion; target a 6–12% upside horizon over 3–6 months, stop-loss at -6% from entry if litigation escalates.
• Purchase a 3-month MCD put spread 5% OTM sized to hedge 1–2% of portfolio value (cost-effective tail hedge) within 7 days to protect vs a headline-driven IV spike and a potential 6–12% downside.
• Increase overweight to KO and UL by 1–2% combined (split equally) within 2 weeks to capture defensive rotation; trim if KO/UL outperform MCD by >4% in 30 days.
• Initiate a 0.5–1% short in POM (Pom Wonderful) within 14 days given higher legal/labeling sensitivity and binary outcomes; cover if POM falls >20% or if plaintiff momentum increases (state AG involvement).
• If class-action is certified or settlement demands exceed $100M (public filings within 30–90 days), reduce MCD position to 0–1% and reallocate proceeds to staples (KO/UL) and absolute-return hedges.